drugset / Trial / NCT04554914
A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the efficacy and safety of tabelecleucel in participants with EBV-associated diseases.
Timeline
- Start
- 2021-07-14
- Primary completion
- 2027-06
- Completion
- 2028-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | tabelecleucel | Cell therapy | 2e+06 cells/kg | Intravenous |